Voxcan

Voxcan is a CRO specialized in non-invasive high-resolution imaging for non-clinical drug development, based in Lyon, France.Voxcan’s core businesses have been in oncology, viral and bacterial infectious diseases, osteo-articular inflammatory diseases and medical devices for 16 years, performing efficacy, biodistribution, mechanistic and proof of concept studies based on in vitro and in vivo models combined with high-resolution imaging in a wide range of small animal species. Voxcan joined the ERBC group in July 2023, giving access to its clients to a full range of non-clinical expertises. This acquisition is in line with ERBC's 3R policy and commitment to reduce the number of animals (up to 80%) used in non-clinical studies and to improve animal welfare. In the infectious disease domain, non-clinical studies can be performed at Voxcan up to Biosafety Level 3, meeting the world's most stringent safety and containment requirements. Voxcan ensures scientific reliability and traceability with studies conducted as per GLP guidelines edited by OECD and ALCOA standards to guarantee data integrity, with a dedicated GLP-like quality assurance system. Voxcan provide a large variety of characterized tumor, bacterial and viral models (including SARS-CoV-2) to test new compounds and cell therapies, in addition of testing medical devices performance and degradation (dermal fillers, osteoarticular implants). Our core expertise in non-clinical 3D CT (computed tomography) imaging, 3D high resolution imaging (µCT i.e. X-ray micro-computed tomography) and non-invasive bioluminescence and fluorescence imaging, ensures longitudinal monitoring of compound efficacy and biodistribution combined with mechanistic analyses based on technologies such as flow cytometry, Luminex and qPCR. By providing high-technology readouts, our ultimate goal is to help Pharma, Biotech and Medical Device companies accelerate the time-to-market of their candidate therapies.